International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 1033-1042 , 15 March 2009

Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610

  • Min Zhang, M.D., Ph.D.

      Affiliations

    • Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Alex Ho, B.S.

      Affiliations

    • American College of Radiology, Philadelphia, PA
    • ,
  • Elizabeth H. Hammond, M.D.

      Affiliations

    • LDS Hospital, Intermountain Health Care, Salt Lake City, UT
    • ,
  • Yoshiyuki Suzuki, M.D., Ph.D.

      Affiliations

    • University of Gunma, Gunma, Japan
    • ,
  • R. Scott Bermudez, M.D.

      Affiliations

    • University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA
    • ,
  • R. Jeffrey Lee, M.D.

      Affiliations

    • LDS Hospital, Intermountain Health Care, Salt Lake City, UT
    • ,
  • Michael Pilepich, M.D.

      Affiliations

    • University of California, Los Angeles, CA
    • ,
  • William U. Shipley, M.D.

      Affiliations

    • Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • ,
  • Howard Sandler, M.D.

      Affiliations

    • University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Li-Yan Khor, M.D.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Alan Pollack, M.D., Ph.D.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Arnab Chakravarti, M.D.

      Affiliations

    • Massachusetts General Hospital, Harvard Medical School, Boston, MA
    • Corresponding Author InformationReprints requests to: Arnab Chakravarti, M.D., Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St., Cox 3, Boston, MA 02114. Tel: (617) 643-3427; Fax: (617) 643-3229

Received 16 January 2008 ,Revised 3 June 2008 ,Accepted 4 June 2008.

References 

  1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921
  2. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3:401–410
  3. Kobayashi K, Hatano M, Otaki M, et al. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA. 1999;96:1457–1462
  4. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152:43–49
  5. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non–small-cell lung cancers. J Clin Oncol. 1999;17:2100–2104
  6. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127–134
  7. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–5074
  8. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808–1812
  9. Ikeguchi M, Ueta T, Yamane Y, et al. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res. 2002;8:3131–3136
  10. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002;20:1063–1068
  11. Chakravarti A, Zhai GG, Zhang M, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 2004;23:7494–7506
  12. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–1081
  13. Zhang M, Mukherjee N, Bermudez RS, et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 2005;64:293–302
  14. Zhang M, Latham DE, Delaney MA, et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005;24:2474–2482
  15. McEleny KR, Watson RW, Coffey RN, et al. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate. 2002;51:133–140
  16. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004;100:751–757
  17. Kishi H, Igawa M, Kikuno N, et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol. 2004;171:1855–1860
  18. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 2002;115:575–585
  19. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54
  20. Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun. 2004;314:902–907
  21. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097–6102
  22. Mahotka C, Liebmann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 2002;9:1334–1342
  23. Mahotka C, Krieg T, Krieg A, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer. 2002;100:30–36
  24. Noton EA, Colnaghi R, Tate S, et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem. 2006;281:1286–1295
  25. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005;24:1994–2007
  26. Kaur P, Kallakury BS, Sheehan CE, et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med. 2004;128:39–43
  27. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  28. Khor LY, Desilvio M, Li R, et al. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys. 2006;66:25–30
  29. Khor LY, Desilvio M, Al-Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer. 2005;104:962–967
  30. Torres-Roca JF, DeSilvio M, Mora LB, et al. Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. Urology. 2007;69:505–509
  31. Wicht H, Maronde E, Olcese J, et al. A semiquantitative image-analytical method for the recording of dose-response curves in immunocytochemical preparations. J Histochem Cytochem. 1999;47:411–420
  32. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–816
  33. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;161141–161154
  34. Shipley WU, Desilvio M, Pilepich MV, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys. 2006;64:1162–1167
  35. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–591
  36. D'Amico AV. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology. 2002;60:32–38
  37. Okada E, Murai Y, Matsui K, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett. 2001;163:109–116
  38. Kennedy SM, O'Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88:1077–1083
  39. Trieb K, Lehner R, Stulnig T, et al. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol. 2003;29:379–382
  40. Lehner R, Lucia MS, Jarboe EA, et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol. 2002;10:134–138
  41. Tonini G, Vincenzi B, Santini D, et al. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer. 2005;92:2225–2232
  42. Fields AC, Cotsonis G, Sexton D, et al. Survivin expression in hepatocellular carcinoma: Correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004;17:1378–1385
  43. Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000;31:1080–1085
  44. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer. 2003;88:115–119
  45. Martinez A, Bellosillo B, Bosch F, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004;164:501–510
  46. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol. 2003;200:620–626
  47. Ferrandina G, Legge F, Martinelli E, et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer. 2005;92:271–277
  48. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell. 2003;14:3325–3341
  49. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315–5320
  50. Krieg A, Mahotka C, Krieg T, et al. Expression of different survivin variants in gastric carcinomas: First clues to a role of survivin-2B in tumour progression. Br J Cancer. 2002;86:737–743

 Supported by Radiation Therapy Oncology Group Grant U10CA21661, Community Clinical Oncology Program Grant U10CA37422, and Grants Stat U10CA32115 from the National Cancer Institute to the Radiation Therapy Oncology Group and the Pennsylvania Department of Health and R01 CA101984-01 (both to A. Pollack).

 Conflict of interest: none.

PII: S0360-3016(08)02473-5

doi: 10.1016/j.ijrobp.2008.06.1489

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 1033-1042 , 15 March 2009

Article Tools

* Image Usage & Resolution